Search results
Showing 196 to 210 of 267 results for carcinoma
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.
View recommendations for HTG97Show all sections
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)
Interventional procedures, IPG478 - Issued: February 2014 --> We have moved interventional procedures guidance 478 to become HealthTech guidance 333. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG447)
Interventional procedures, IPG447 - Issued: March 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 478.
Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)
NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
LiMAx system for assessing the functional capacity of the liver (MIB168)
NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .
We have moved interventional procedures guidance 214 to become HealthTech guidance 138. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 2 to become HealthTech guidance 1. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .